Global Double Barreled Antibodies Drug Sales (BLINCYTO & Removab), Pipeline Analysis (By Phase, Technology, and Indication), & Global Market Forecasts 2022

Published: Apr, 2017 | Pages: 80 | Publisher: RNCOS
Industry: Healthcare | Report Format: Electronic (PDF)

The double barreled or bi-specific antibodies concept is progressively gaining traction in the biopharmaceutical industry owing to several therapeutic advantages, as well as their potential to address challenges being faced with the mAb based therapies. Bi-specific antibodies are artificial antibodies developed by joining together two monoclonal antibodies or their parts that target different epitopes. The resulting bi-specific antibody has binding affinities for two or three different epitopes concomitantly.

According to the RNCOS report entitled “Global Double Barreled Antibodies Drug Sales (BLINCYTO & Removab), Pipeline Analysis (By Phase, Technology, and Indication), & Global Market Forecasts 2022”, the double barreled antibodies market is anticipated to reach US$ 604.9 Million by 2022. In this report, there is in-depth market analysis of BLINCYTO and Removab. The double barreled antibodies market is still in its infancy. With the European Medicines Agency approval of Removab in 2009, a great deal of interest has been generated in the bi-specific antibody market. The bi-specific antibodies pipeline is rich and diverse, and has drugs being developed for both oncological and non-oncological indications. These drugs are based on various technological platforms developed by Roche, Amgen, AbbVie, Ablynx, Affimed, and MacroGenics amongst others. The antibody platforms are based on the concepts of chemical cross-linking, hybridomas, as well as recombinant techniques.

During the course of our research, we found bi-specific antibodies currently in different stages of clinical development. Most of these are industry sponsored, and around 2-3 of the bi-specific antibody drugs amongst them are expected to be launched by the end of this decade. In addition to the clinical pipeline, over 30 molecules have been identified which are currently in preclinical/discovery phase. Technological advancements, particularly in the bi-specific antibodies purification will ensure the development of products with improved safety, potency, and efficacy profile. As more products move from pipeline to the market, an increase in the investment in this bi-specific antibodies development is expected from various quarters in coming years. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry’s growth.

In the end, the report enlists some of the key players in the double barreled antibodies market including in-short business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses. Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.

Table of Content

1. Analyst View

2. Research Methodology

3. Double Barreled Antibodies – An Introduction

4. Double Barreled Antibodies Market Outlook to 2022
4.1 BLINCYTO
4.1.1 Market Potential
4.1.2 Actual Market Size
4.2 Removab
4.2.1 Market Potential
4.2.2 Actual Market Size

5. Double Barreled Antibodies Pipeline Analysis
5.1 By Clinical Phase
5.2 By Indication
5.3 By Technology

6. Market Dynamics
6.1 Drivers
6.1.1 Rising Global Cancer Epidemics
6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional mAbs
6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy
6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies
6.2 Challenges
6.2.1 Production Hurdles in Double Barreled Antibodies Development
6.2.2 Regulatory Challenges

7. Current Status of Potential Double Barreled Antibodies in Pipeline
7.1 BLINCYTO/Blinatumomab – Amgen Inc.
7.2 ABT-122 – AbbVie Inc.
7.3 MCLA-128 – Merus N.V.
7.4 ALX-0761/M1095 - Ablynx
7.5 MGD006/S80880 – MacroGenics, Inc.
7.6 ZW25 – Zymeworks Inc.

8. Trends and Developments
8.1 Bi-specific Antibody Application for Tumor Therapy
8.2 Bi-specific Antibodies Development Against Myeloma
8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics
8.4 B-specific Antibody Development against Multiple Ebola viruses

9. Strategic Collaborations in the Double Barreled Antibody Industry

10. Competitive Assessment
10.1 Amgen Inc.
10.2 F. Hoffman La Roche Ltd.
10.3 AbbVie Inc.
10.4 OncoMed Pharmaceuticals, Inc.
10.5 Glenmark Pharmaceuticals Limited
10.6 Xencor, Inc.
10.7 MacroGenics, Inc.
10.8 Aptevo Therapeutics Inc.
10.9 Ligand Pharmaceuticals, Inc.
10.10 Regeneron Pharmaceuticals, Inc.
10.11 Fresenius SE & Co. KGaA
10.12 Merus N.V.

List of Tables:

Table 4-1: Global - Potential Patients for BLINCYTO (2017)
Table 4-2: Global - Potential Patients for BLINCYTO (2020)
Table 4-3: Global - Ongoing Trials for BLINCYTO
Table 4-4: Global - Potential Patients for Removab, 2016
Table 4-5: Global - Potential Patients for Removab, 2020
Table 5-1: Global - Double Barreled Antibodies Pipeline
Table 9-1: Global - Strategic Collaborations in the Double Barreled Antibody Industry
Table 10-1: Top Companies by Double Barreled Antibodies in Pipeline, 2016
Table 10-2: Amgen Inc. - Product Portfolio
Table 10-3: Amgen Inc. - Double Barreled Antibodies in Pipeline
Table 10-4: Amgen Inc. - Key Financials (Million US$), 2013-2015
Table 10-5: F. Hoffman La Roche Ltd. - Double Barreled Antibodies in Pipeline
Table 10-6: F. Hoffman La Roche Ltd. - Key Financials (Million US$), 2014-2016
Table 10-7: AbbVie Inc. - Double Barreled Antibodies in Pipeline
Table 10-8: AbbVie Inc. - Key Financials (Million US$), 2014-2016
Table 10-9: OncoMed Pharmaceuticals, Inc. - Double Barreled Antibodies in Pipeline
Table 10-10: OncoMed Pharmaceuticals, Inc. - Key Financials (Million US$), 2014-2016
Table 10-11: Glenmark Pharmaceuticals Limited, - Double Barreled Antibodies in Pipeline
Table 10-12: Glenmark Pharmaceuticals Limited, - Key Financials (Million US$), FY 2014-2016
Table 10-13: Xencor, Inc. - Double Barreled Antibodies in Pipeline
Table 10-14: Xencor, Inc. - Key Financials (Million US$), 2014-2016
Table 10-15: MacroGenics, Inc. - Double Barreled Antibodies in Pipeline
Table 10-16: MacroGenics, Inc. - Key Financials (Million US$), 2014-2016
Table 10-17: Aptevo Therapeutics - Double Barreled Antibodies in Pipeline
Table 10-18: Ligand Pharmaceuticals, Inc. - Double Barreled Antibodies in Pipeline
Table 10-19: Ligand Pharmaceuticals, Inc. - Key Financials (Million US$), 2014-2016
Table 10-20: Regeneron Pharmaceuticals, Inc. - Double Barreled Antibodies in Pipeline
Table 10-21: Regeneron Pharmaceuticals, Inc. - Key Financials (Million US$), 2014-2016
Table 10-22: Fresenius SE & Co. KGaA - Product Portfolio
Table 10-23: Fresenius SE & Co. KGaA - Key Financials (Million US$), 2014-2016
Table 10-24: Merus N.V. - Double Barreled Antibodies in Pipeline

List of Figures:

Figure 3-1: Double Barreled Antibodies - Mechanism of Action
Figure 4-1: Global - Double Barreled Antibodies Market (Million US$), 2016-2022
Figure 4-2: Global - BLINCYTO Market (Million US$), 2015 & 2016
Figure 4-3: Global - Removab Market (Million US$), 2012 & 2013
Figure 5-1: Global - Double Barreled Antibodies Pipeline by Clinical Phase (%), 2016
Figure 5-2: Global - Double Barreled Antibodies Pipeline by Indication (%), 2016
Figure 5-3: Global - Double Barreled Antibodies Pipeline by Technology (%), 2016
Figure 6-1: Global - Cancer & Other Non-Communicable Disease Epidemics (%), 2016
Figure 10-1: Amgen Inc. - Breakup of Revenue by Geography (%), 2015
Figure 10-2: F. Hoffman La Roche Ltd. - Breakup of Group Sales by Business Segments (%), 2016
Figure 10-3: F. Hoffman La Roche Ltd. - Breakup of Group Sales by Geography (%), 2016
Figure 10-4: AbbVie Inc. - Breakup of Net Revenues by Geography (%), 2016
Figure 10-5: Glenmark Pharmaceuticals Limited, - Breakup of Revenue by Geography (%), FY 2016
Figure 10-6: Xencor, Incl. - Breakup of Revenue by Product Programs (%), 2016
Figure 10-7: Ligand Pharmaceuticals, Inc. - Breakup of Revenue by Operations (%), 2016
Figure 10-8: Ligand Pharmaceuticals, Inc. - Breakup of Royalty Revenue by Program (%), 2016
Figure 10-9: Ligand Pharmaceuticals, Inc. - Breakup of Material Sales by Use (%), 2016
Figure 10-10: Fresenius SE & Co. KGaA - Breakup of Sales by Business Segments (%), 2016
Figure 10-11: Fresenius SE & Co. KGaA - Breakup of Sales by Geography (%), 2016